Search details
1.
Empagliflozin in Patients with Chronic Kidney Disease.
N Engl J Med
; 388(2): 117-127, 2023 01 12.
Article
in English
| MEDLINE | ID: mdl-36331190
2.
Proteomic Evolution from Acute to Post-COVID-19 Conditions.
J Proteome Res
; 23(1): 52-70, 2024 01 05.
Article
in English
| MEDLINE | ID: mdl-38048423
3.
Executive summary of the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease: known knowns and known unknowns.
Kidney Int
; 105(4): 684-701, 2024 Apr.
Article
in English
| MEDLINE | ID: mdl-38519239
4.
Outcomes for clinical trials involving adults with chronic kidney disease: a multinational Delphi survey involving patients, caregivers, and health professionals.
Nephrol Dial Transplant
; 2024 Jan 17.
Article
in English
| MEDLINE | ID: mdl-38236705
5.
Global variability of vascular and peritoneal access for chronic dialysis.
Nephrology (Carlton)
; 29(3): 135-142, 2024 Mar.
Article
in English
| MEDLINE | ID: mdl-38018697
6.
Global variations in funding and use of hemodialysis accesses: an international report using the ISN Global Kidney Health Atlas.
BMC Nephrol
; 25(1): 159, 2024 May 08.
Article
in English
| MEDLINE | ID: mdl-38720263
7.
The Kidney Failure Risk Equation: Evaluation of Novel Input Variables including eGFR Estimated Using the CKD-EPI 2021 Equation in 59 Cohorts.
J Am Soc Nephrol
; 34(3): 482-494, 2023 03 01.
Article
in English
| MEDLINE | ID: mdl-36857500
8.
Major cardiovascular events and subsequent risk of kidney failure with replacement therapy: a CKD Prognosis Consortium study.
Eur Heart J
; 44(13): 1157-1166, 2023 04 01.
Article
in English
| MEDLINE | ID: mdl-36691956
9.
Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis.
N Engl J Med
; 382(7): 622-631, 2020 02 13.
Article
in English
| MEDLINE | ID: mdl-32053298
10.
Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex: A Post Hoc Analysis of the CREDENCE Randomized Clinical Trial.
Am J Kidney Dis
; 82(1): 84-96.e1, 2023 07.
Article
in English
| MEDLINE | ID: mdl-36889425
11.
Are patients with primary glomerular disease at increased risk of malignancy?
Nephrol Dial Transplant
; 2023 Dec 09.
Article
in English
| MEDLINE | ID: mdl-38070875
12.
Long-term effect of COVID-19 infection on kidney function among COVID-19 patients followed in post-COVID-19 recovery clinics in British Columbia, Canada.
Nephrol Dial Transplant
; 38(12): 2816-2825, 2023 Nov 30.
Article
in English
| MEDLINE | ID: mdl-37349962
13.
Kidney protection with canagliflozin: A combined analysis of the randomized CANVAS program and CREDENCE trials.
Diabetes Obes Metab
; 25(8): 2331-2339, 2023 08.
Article
in English
| MEDLINE | ID: mdl-37184050
14.
The sodium-glucose cotransporter-2 inhibitor canagliflozin does not increase risk of non-genital skin and soft tissue infections in people with type 2 diabetes mellitus: A pooled post hoc analysis from the CANVAS Program and CREDENCE randomized double-blind trials.
Diabetes Obes Metab
; 25(8): 2151-2162, 2023 08.
Article
in English
| MEDLINE | ID: mdl-37161691
15.
Association of Clonal Hematopoiesis of Indeterminate Potential with Worse Kidney Function and Anemia in Two Cohorts of Patients with Advanced Chronic Kidney Disease.
J Am Soc Nephrol
; 33(5): 985-995, 2022 05.
Article
in English
| MEDLINE | ID: mdl-35197325
16.
Vaccine Effectiveness Against SARS-CoV-2 Infection and Severe Outcomes in the Maintenance Dialysis Population in Ontario, Canada.
J Am Soc Nephrol
; 33(4): 839-849, 2022 04.
Article
in English
| MEDLINE | ID: mdl-35264455
17.
Estimated Glomerular Filtration Rate, Albuminuria, and Adverse Outcomes: An Individual-Participant Data Meta-Analysis.
JAMA
; 330(13): 1266-1277, 2023 10 03.
Article
in English
| MEDLINE | ID: mdl-37787795
18.
Accuracy, Reproducibility and User Experience With Standardized Instructions for Measurement of Total Kidney Volume in Autosomal Dominant Polycystic Kidney Disease.
Can Assoc Radiol J
; 74(2): 343-350, 2023 May.
Article
in English
| MEDLINE | ID: mdl-36063401
19.
Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease: Insights From the CREDENCE Trial.
Circulation
; 143(18): 1735-1749, 2021 05 04.
Article
in English
| MEDLINE | ID: mdl-33554616
20.
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
N Engl J Med
; 380(24): 2295-2306, 2019 06 13.
Article
in English
| MEDLINE | ID: mdl-30990260